Show simple item record

dc.contributor.authorThatcher, Nick
dc.date.accessioned2010-04-23T10:46:38Z
dc.date.available2010-04-23T10:46:38Z
dc.date.issued1994-03
dc.identifier.citationTreatment evaluation of combined modality therapy: 'what can we obtain today from phase II trials?'. 1994, 10 Suppl 1:S117-33 Lung Canceren
dc.identifier.issn0169-5002
dc.identifier.pmid8087501
dc.identifier.doi10.1016/0169-5002(94)91674-8
dc.identifier.urihttp://hdl.handle.net/10541/97281
dc.description.abstractDemonstration of activity is the major goal of Phase II studies. Other end points-duration of response, survival (relapse free in complete responders), progression free interval, changes in performance status and quality of life also provide useful information. From these data a decision to continue or discard a particular therapy can be considered. Various handicaps including variability in response reporting, heterogeneity of patient populations, inadequate reporting of failure patterns, causes of death, performance status changes and quality of life hinder interpretation of Phase II data. Nevertheless, Phase II studies have defined prognostic groups, beneficial changes in performance status and have helped formulate novel management approaches. Targeting particular prognostic groups, investigating dose-intensive regimens with haemopoietic growth-factor support and novel combined-modality approaches have all been generated through Phase II investigations.
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshActuarial Analysis
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshCarcinoma, Small Cell
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshClinical Trials, Phase II as Topic
dc.subject.meshCombined Modality Therapy
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshMale
dc.subject.meshMulticenter Studies as Topic
dc.subject.meshOutcome Assessment (Health Care)
dc.subject.meshPrognosis
dc.subject.meshProportional Hazards Models
dc.subject.meshQuality Control
dc.subject.meshQuality of Life
dc.subject.meshReproducibility of Results
dc.subject.meshSurvival Analysis
dc.subject.meshTreatment Outcome
dc.titleTreatment evaluation of combined modality therapy: 'what can we obtain today from phase II trials?'.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital, CRC Department of Medical Oncology, Manchester, UK.en
dc.identifier.journalLung Canceren
html.description.abstractDemonstration of activity is the major goal of Phase II studies. Other end points-duration of response, survival (relapse free in complete responders), progression free interval, changes in performance status and quality of life also provide useful information. From these data a decision to continue or discard a particular therapy can be considered. Various handicaps including variability in response reporting, heterogeneity of patient populations, inadequate reporting of failure patterns, causes of death, performance status changes and quality of life hinder interpretation of Phase II data. Nevertheless, Phase II studies have defined prognostic groups, beneficial changes in performance status and have helped formulate novel management approaches. Targeting particular prognostic groups, investigating dose-intensive regimens with haemopoietic growth-factor support and novel combined-modality approaches have all been generated through Phase II investigations.


Files in this item

This item appears in the following Collection(s)

Show simple item record